Most Read Articles
Jairia Dela Cruz, 15 Apr 2019
Use of oral contraceptives (OC) confers some protection against bone loss in patients with anorexia nervosa (AN), a study has found. Areal bone mineral density preservation improves with longer durations of OC use and shorter delays between disease onset and OC initiation, and appears to be most pronounced in patients more severe forms of AN.
17 Oct 2019
Use of direct acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection is feasible during pregnancy, as these drugs are highly effective and treatment duration is relatively short, according to a study. In addition, DAA treatment helps improve maternal health and prevent vertical transmission.
Rachel Soon, 16 Nov 2019

The third Pharmaceutical Industry Pharmacists Insight (PIPI 3.0) symposium will highlight areas of the pharmaceutical industry often overlooked by those entering the pharmacy profession.

Pearl Toh, 17 Apr 2019
A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.

Ceritinib ups hyperglycaemia risk

14 Nov 2019
One million deaths in China occur each year as a result of diabetic complications.

Ceritinib use appears to carry a significant risk of developing hyperglycaemia, a new Japan study has found.

Accessing the Japan Adverse Drug Even Report (JADER) database, researchers identified signals of hyperglycaemia and related events. They identified 7,837 such cases out of 887,636 adverse drug reactions reported in the databases. Reported odds ratios (ROR) were calculated using a two-by-two contingency table.

Of the three anaplastic lymphoma kinase inhibitors (ALKIs), only ceritinib resulted in significant RORs. There were 429 database entries that initiated ceritinib use before September 2017; four of them developed hyperglycaemia, indicating an insignificant risk (ROR, 1.06, 95 percent confidence intervals [CI], 0.39–2.83).

On the other hand, seven of 132 patients who started ceritinib medication after September 2017 showed hyperglycaemia and related events. The resulting risk estimate was significant (ROR, 6.29, 95 percent CI, 2.94–13.5).

“The insignificant ROR before September 2017 might be biased due to the limited case application and/or possible prior use of crizotinib or alectinib,” researchers explained.

A similar pattern of effect was reported when JADER datapoints with use of antidiabetes agents were excluded. Of the 545 remaining users of ceritinib, eight developed hyperglycaemia events (ROR, 2.54, 95 percent CI, 1.27–5.12).

In any of the analyses performed above, crizotinib and alectinib, both ALKIs, did not result in a significantly higher likelihood of developing hyperglycaemia.

“Clinicians including diabetologists and oncologists should emphasize vigilance for ceritinib-associated hyperglycaemia,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 15 Apr 2019
Use of oral contraceptives (OC) confers some protection against bone loss in patients with anorexia nervosa (AN), a study has found. Areal bone mineral density preservation improves with longer durations of OC use and shorter delays between disease onset and OC initiation, and appears to be most pronounced in patients more severe forms of AN.
17 Oct 2019
Use of direct acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection is feasible during pregnancy, as these drugs are highly effective and treatment duration is relatively short, according to a study. In addition, DAA treatment helps improve maternal health and prevent vertical transmission.
Rachel Soon, 16 Nov 2019

The third Pharmaceutical Industry Pharmacists Insight (PIPI 3.0) symposium will highlight areas of the pharmaceutical industry often overlooked by those entering the pharmacy profession.

Pearl Toh, 17 Apr 2019
A contraceptive vaginal system (Annovera) releasing a combination of segesterone acetate and ethinyl estradiol (SA/EE) effectively inhibits ovulation up to a year even at low systemic levels of SA, reports a review study presented at ENDO 2019.